-
-
-
-
-
-
-
AstraZeneca results: FY and Q4 2025
-
-
-
-
-
-
-
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
-
-
-
-
-
-
-
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial
-
-
-
-
-
-
-
AstraZeneca (AZN) and Harbour BioMed Enter Global Strategic Collaboration to Discover and Develop Next-Generation Therapeutic Antibodies
-
-
-
-
-
-
-
AstraZeneca’s H1 and Q2 2024 Financial Results
-
-
-
-
-
-
-
Q1 2024 results
-
-
-
-
-
-
-
AstraZeneca Full year and Q4 2023 Financial Results
-
1,168,075 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

